HAMILTON, BM / ACCESS Newswire / March 24, 2026 / Altamira Therapeutics ("Altamira" or the "Company") (OTCID:CYTOF) today announced that it will release its annual report and financial statements for the fiscal year ended December 31, 2025 on March 31, 2026 at 9 am EDT.
About Altamira Therapeutics
Altamira Therapeutics is developing and supplying peptide-based nanoparticle technologies for efficient nucleic acid delivery (xPhore™ platform). The versatile delivery platform is suited for different nucleic acid modalities, including siRNA, mRNA, circRNA, as well as DNA, and made available to pharma or biotech companies through out-licensing. The Company has two proprietary flagship programs based on xPhore and siRNA payloads: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. In addition, Altamira holds a 49% stake in Altamira Medica AG, which commercializes Bentrio, an OTC nasal spray for allergic rhinitis, and owns several assets for CNS indications which it intends to partner / divest. Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com/
Investor Contact:
SOURCE: Altamira Therapeutics Ltd.
View the original press release on ACCESS Newswire
COMTEX_475857938/2457/2026-03-24T09:00:43